Papers
7
Total Citations
199
H-Index
6
About
Alan So is a leading urologic surgeon and researcher whose work has transformed the surgical management of benign prostatic hyperplasia (BPH), particularly for patients with large prostate glands. His primary research focuses on advancing minimally invasive treatments for lower urinary tract symptoms, with a special emphasis on Aquablation therapy—a novel, robotically assisted water-jet ablation technique. Dr. So has been instrumental in demonstrating the safety and durability of Aquablation for prostates between 80 and 150 cc, a population historically limited to more invasive options like open prostatectomy. His landmark WATER II trial, with five-year results published in 2023 (49 citations), showed sustained symptom relief and low complication rates, establishing a new standard for large-gland BPH care. His 2019 paper on one-year Aquablation outcomes (63 citations) remains a foundational reference in the field. Beyond BPH, Dr. So has contributed to risk prediction in radical cystectomy and oncologic outcomes in testicular cancer. His work has been published in top-tier journals like the *Journal of Urology*, and his comparative analyses of Aquablation across prostate sizes have guided clinical decision-making worldwide. Through rigorous clinical trials and multi-institutional collaborations, Dr. So continues to shape the future of urologic surgery.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6Aquablation among novice users in Canada: A WATER II subpopulation analysis17 citations · 2018
- 7